A recent report highlights significant disparities in the prescribing of new medications across Scotland's health boards, particularly for weight management. NHS Western Isles is prescribing weight loss and diabetes drugs at nearly three times the rate of other boards, with a noted focus on GLP-1 medications, which were recently approved for weight management.
The Association of the British Pharmaceutical Industry (ABPI) emphasized the need for improved planning to address these inequalities. The Scottish government is reviewing the findings as part of broader health board reforms aimed at enhancing access to services and reducing variations in treatment availability.
The high prescribing rates in NHS Western Isles may indicate a proactive approach to obesity management. Readers should monitor how the Scottish government's reforms impact access to GLP-1 medications across other boards and whether this leads to improved health outcomes.